Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns

Table 6

Median survival of patients with soft tissue sarcoma receiving different treatments.

Treatment	Progression-free survival (month)		Overall survival (month)
	Median	95% CI	Median	95% CI
First line	—	—	15.7	—
Second line	5.2	3.6–6.8	17.9	—
Beyond second line	2.9	0.5–5.3	11.7	2.4–21.0
Anlotinib	5.4	4.9–6.0	22.8	12.4–33.2
Anlotinib plus chemotherapy	5.7	3.3–8.1	17.9	13.3–22.5
Anlotinib plus radiotherapy	1.4	—	6.3	—
Total	5.4	4.1–6.8	17.9	11.2–24.6